FORM 4

Check this box if no longer

Form 5 obligations may

subject to Section 16. Form 4 or

continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB Number: 3235-0287 Estimated average burden 0.5

OMB APPROVAL

hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Stamler David A			•			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
(First)	(Middle)	3. Date of Earliest 03/16/2015	t Transaction (Month	ar)		v Off	fficer (give title	10% Owner Other (specify				
3333 N. TORREY PINES COURT SUITE 400								Chief Medical Officer				
CA	92037	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting				
(State)	(Zip)	Person										
	Table I - Nor	n-Derivative Securi	ties Acquired, Disp	osed of	, or B	eneficially	Owne	.d				
1. Title of Security (Instr. 3)				Transaction Code (Instr.		າ (A) or Dis	sposed	d Of (D)	5. Amount of Securities Beneficially Owned	Ownership Form: Direct (D)	Beneficial Ownership	
				Code	v	Amount	(A) or (D)	Price	Following Reported Transaction(s) (Instr. 3 and 4)	or Indirect (I) (Instr. 4)	(Instr. 4)	
		03/16/2015		M		3,000	A	\$0.9	3,983	D		
		03/16/2015		S (1)		400	D	\$79.549 (2)	3,583	D		
		03/16/2015		S (1)		2,600	D	\$80.075	983	D		
<u> </u>	(First) (PINES COURT  CA (State)	(First) (Middle)  PINES COURT  CA 92037  (State) (Zip)  Table I - Non  ity (Instr. 3)	Auspex Pharmaceu   3. Date of Earliest   03/16/2015     4. If Amendment,	Auspex Pharmaceuticals, Inc. [AS]  (First) (Middle)  PINES COURT  4. If Amendment, Date of Original File  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disprity (Instr. 3)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  03/16/2015	Auspex Pharmaceuticals, Inc. [ASPX]  3. Date of Earliest Transaction (Month/Day/Ye 03/16/2015  4. If Amendment, Date of Original Filed (Month Cate)  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, ity (Instr. 3)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  2. Transaction Date, if any (Month/Day/Year)  (Month/Day/Year)  Code (Instr. 3)  Code (Instr. 3)  O3/16/2015  M  O3/16/2015	Auspex Pharmaceuticals, Inc. [ASPX]  3. Date of Earliest Transaction (Month/Day/Year)  O3/16/2015  4. If Amendment, Date of Original Filed (Month/Day/  CA 92037  (State) (Zip)  Table 1 - Non-Derivative Securities Acquired, Disposed of, or British (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  O3/16/2015  M  O3/16/2015  Auspex Pharmaceuticals, Inc. [ASPX]  3. Date of Earliest Transaction (Month/Day/Year)  4. If Amendment, Date of Original Filed (Month/Day/Year)  Execution Date, if any (Month/Day/Year)  O3/16/2015  M  O3/16/2015  S (i)	Auspex Pharmaceuticals, Inc. [ASPX]  (First) (Middle)  PINES COURT  4. If Amendment, Date of Original Filed (Month/Day/Year)  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially (Instr. 3)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (A) or Disposed of, or Beneficially (Instr. 3)  (Month/Day/Year)  (Month/Day/Year)  (A) or Disposed of, or Beneficially (A) or Disposed of, or Beneficially (A) or Disposed of, or Beneficially (B) or Date (Instr. 3)  (A) or Disposed of, or Beneficially (B) or Date (Instr. 4) or Disposed of, or Beneficially (B) or Date (Instr. 4) or Disposed of, or Beneficially (B) or Date (Instr. 5) or Date (Instr. 6) or Date (Instr.	Auspex Pharmaceuticals, Inc. [ASPX]  (First) (Middle)  PINES COURT  4. If Amendment, Date of Original Filed (Month/Day/Year)  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owne Execution Date (Month/Day/Year)  (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  3. Date of Earliest Transaction (Month/Day/Year)  4. If Amendment, Date of Original Filed (Month/Day/Year)  2. Transaction Date (Instr. 3)  (A) or Disposed (Instr. 3, 4 and 5)  (Code V Amount Or (D)  03/16/2015  M 3,000 A  03/16/2015  S (1) 400 D	Auspex Pharmaceuticals, Inc. [ASPX]   (Check all a Dir X Off bel	Auspex Pharmaceuticals, Inc. [ASPX]  (First) (Middle)  (A. If Amendment, Date of Original Filed (Month/Day/Year)  (State) (Zip)  (State) (A. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)  (State) (Zip)  (Month/Day/Year)  (Month/Day/	Auspex Pharmaceuticals, Inc. [ ASPX ] (Check all applicable) Director 10% O X Officer (give title below) Chief Medical Officer  4. If Amendment, Date of Original Filed (Month/Day/Year) (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned ity (Instr. 3)  2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)  2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned  2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)  2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)  2. Transaction Date (Month/Day/Year) (M	

				(e.g.,	puts, ca	alls, w	arrants	s, options, co	nvertible sec	curities)					
Derivative Security	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	Securities Beneficially Owned	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Be Ow (In:
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$0.9	03/16/2015		M			3,000	(4)	03/10/2021	Common Stock	3,000	\$0.00	25,274	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

## **Explanation of Responses:**

- 1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 23, 2014.
- 2. This transaction was executed in multiple trades at prices ranging from a low of \$79.14 to a high of \$79.78. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 3. This transaction was executed in multiple trades at prices ranging from a low of \$79.98 to a high of \$80.25. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 4. The original option grant to purchase 30,934 shares of common stock was subject to monthly vesting over a four-year period beginning on February 15, 2011 and became fully vested on January 15, 2015.

## Remarks:

/s/ Robert Daniel, Attorney-in-fact 03/17/2015

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

